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ABSTRACT 
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Background: 
Hypothyroidism is the second common endocrine disorder next to Diabetes 
Mellitus. One of the major target organs of hypothyroidism is the cardiovascular system 
and it is very sensitive to even minimal deviations from normal levels. The 
cardiovascular manifestation of hypothyroidism includes decreased cardiac contractility, 
decreased cardiac output, increase in peripheral vascular resistance. The electrical 
abnormalities seen in the ECG consists of bradycardia, low voltage complexes, varying 
degrees of heart block and decreased systolic and diastolic functions of the heart. This is 
also associated with disturbances in autonomic balance which may lead adverse cardiac 
events like arrhythmias in these patients. It is also observed that treatment with L 
thyroxine in these patients will be helpful in preventing these complications. 
Aim and objectives: 
              To assess the Resting Heart Rate Variability and Echocardiography in normal 
and hypothyroid (female) patients before and after treatment.  
Materials and Methods: 
The study included thirty newly diagnosed female hypothyroid patients with elevated 
seum TSH levels and age matched normal healthy individuals as controls. They were 
assessed with HRV analysis and ECHO before treatment and reassessed after 3 months of 
treatment with L-thyroxine. After attaining euthyroid levels by measuring the serum TSH 
levels they reassessed with HRV and ECHO. 
Results: 
There was autonomic imbalance with increased sympathetic activity and decreased 
parasympathetic activity in hypothyroid females before treatment as shown by very 
highly significant (p<0.000) changes in frequency domain measures of HRV like 
increased LF (nu) and decreased HF (nu) and increased LH/HF ratio, decreased time 
domain measures. There were also very highly significant (p<0.000) changes in ejection 
fraction and LVID (both end systolic and end diastolic) parameters. After treatment with 
L-thyroxine the changes were comparable with normal to normal individuals. The 
elevated serum TSH levels were also shows highly significant (p<0.001) after treatment. 
Conclusion: 
This study shows that replacement therapy with L Thyroxine will play an essential role in 
preventing the cardio vascular complications of hypothyroidism like autonomic 
imbalance. As HRV and ECHO are both noninvasive in nature, both of these can be used 
to assess these patients of hypothyroidism for CVS complications and regular follow up 
after treatment. 
Key words: Hypothyroidism, L-Thyroxine, Heart Rate Variability, Echocardiography  
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INTRODUCTION 
Thyroid disorders have become a common endocrine disorder in the 
world nowadays. World Health Organization (WHO) has reported that 
more than 700 million people are affected by it globally. It is expected to be 
even more prevalent than diabetic. Among all the Thyroid disorders, 
Hypothyroidism and Hyperthyroidism contribute to the major proportion 
with 5-15% and 0.3-0.6% respectively (Demers L.M et al, Spencer C et 
al)
1 
. 
The incidence of thyroid disorders has increased considerably; 
currently about 42 million people in India are having thyroid abnormalities 
(Delange F et al, de Benoist B et al, Burgi H et al)
2
. The prevalence of 
thyroid disorders is 8 to 10 times more common in women than men. The   
prevalence of hypothyroidism is higher than hyperthyroidism, higher in 
females than in males, and increases with age, suggesting that hypothyroid 
disorders could merit more concern. 
It is well documented that diabetes, hypertension, coronary artery 
diseases which are It has been found that the non – communicable diseases 
like diabetes, hypertension, Coronary artery heart disease are mostly due to 
increased stress and sedentary life style. (Okada K et al)
3
, and recently it 
has been postulated that basic pathophysiology behind  these disorders is 
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mainly autonomic imbalance (Frontoni S. et al, Bracaglia D, et al, Gigli F 
et al)
4
. 
ACTION OF THYROID HORMONE ON CARDIOVASCULAR 
SYSTEM 
Thyroid hormones are the main regulators of the basal metabolism in 
all major cells of our body and this will have an influence on the autonomic 
balance (Buchheit M et al, Simno C et al)
5
. Generally hypothyroidism is a 
hypo metabolic state and sympathetic system functions are expected to be 
decreased in this state (Jameson JL et al, Anthony P et al, Weetman AS 
et al)
6
. 
 
Thyroid hormone has multiple effects on the cardiovascular system. 
These include increased cardiac contractility, increased cardiac output, 
decreased systemic vascular resistance and electrophysiological and pro-
angiogenic effects.  The cellular and molecular mechanisms that have been 
proposed for this include genomic and non – genomic (extra nuclear) 
actions.  
In genomic actions the active form of thyroid hormone, 
triiodothyronine (T3), enters the nucleus and binds to the specific nuclear 
receptors (TR alpha and TR beta). The T3 receptor complex then binds to 
thyroid –hormone response elements (TREs) in the promoter regions of 
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specific target genes and modifies their expression. These are genomic 
actions. The more rapid non-genomic actions includes the regulation of 
membrane ion channels or pumps and may involve the activation of several 
signaling pathways, including protein kinase C (PKC), mitogen activated 
protein kinases (MAPKs) 6, 7 and Akt8. 
The heart and the peripheral circulation are the most commonly 
affected system by the thyroid dysfunction (Ievleva GI et al, Teslia EF et 
al, Buganov AA et al)
7
 and many of the signs and symptoms of  seen in 
hypothyroidism could be because of the reduced activity of thyroid 
hormone on CVS (Galetta F et al, Franzoni F et al, Fallahi P et al)
8
. 
It has long been recognized that decreased thyroid hormone activity 
may produce cardiovascular abnormalities like bradycardia, decreased 
cardiac output, diastolic dysfunction, mild diastolic hypertension, increased 
peripheral vascular resistance, dilated cardiomyopathy and increased 
incidence of coronary atherosclerosis which are associated with impaired 
sympatho-vagal balance of the heart. 
It has been observed that in  patients with defective thyroid function 
there may a reduced autonomic modulation of cardiac activities (Galetta F 
et al, Franzoni F et al, Fallahi P et al)
8
. This has also been reported that in 
hypothyroid individuals may have autonomic nervous system disturbance 
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with a increased level of vagal activity which may be corrected  with 
thyroxine treatment (Xing H et al, Shen Y et al, Chen H et al)
9
.  
Heart diseases are more alarming today due to their life threatening 
complications. Health awareness among the public also increasing 
nowadays and they are ready to undergo available required investigations to 
detect their diseases as early as possible. 
From a large number of studies we have found out the significant 
relationship between the autonomic nervous system and cardiovascular 
morbidity including sudden cardiac death (Galetta F et al, Franzoni F et 
al, Fallahi P et al)
8
. There were also studies to show the association of 
lethal arrhythmias with signs of either increased sympathetic or decreased 
parasympathetic activity (Barczynski M et al, Tabor S et al, Thor P et 
al)
10
. This has encouraged for the development of quantitative markers of 
autonomic activity. One such that is the Heart rate variability analysis 
which was used to evaluate the sympathovagal balance in newly diagnosed 
hypothyroid female individuals in this study. 
HEART RATE VARIABILITY ANALYSIS 
Heart rate variability analysis is an analysis of beat to beat variations 
in heart rate, is an important and widely used non- invasive method to 
evaluate the integrity and autonomic function of heart. Levy MN et al
11
, 
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says that heart rate is due to intrinsic activity of Sino atrial node 
(pacemaker of heart) and the modulating influences of autonomic nervous 
system. 
The intrinsic firing rate of un - innervated human SA node is 100 
beats per minute (Ganong WF et al)
12
.  If it is innervated, the sympathetic 
stimulation will increase the heart rate, while parasympathetic stimulation 
through the vagus nerve will decrease the heart rate. Normally there is 
predominance of vagal tone over sympathetic tone which keeps the resting 
heart rate below 100 per minute. 
Heart rate in an individual is measured by counting the number of 
heart beats per minute. Even in the resting state the duration of cardiac 
cycle of all heart beats occurring in one minute, is not at all same. There is 
beat to beat variability of RR intervals in milliseconds. This beat to beat 
variation is known as HEART RATE VARIABILITY. The RR interval is 
defined as the interval of time between the two consecutive heartbeats and 
it is measured in millisecond (ms). It can be measured from 
Electrocardiography. The autonomic balance between sympathetic and 
parasympathetic nervous activities on the heart can be determined by 
analysing the  variations of this interval. 
The fact that autonomic innervation of SA node produces variability 
in heart rate has been proved by doing tests that stimulates these 
6 
 
innervating nerves. The heart rate is being constantly influenced by external 
and internal stimuli and regulated by the autonomic nervous system. This 
variation of the heart rate from beat to beat is known as the heart rate 
variability (HRV). Heart rate variability reflects the amount of changes in 
the length of the intervals. This can be assessed by a group of tests called as 
cardiac autonomic function tests which evaluate both parasympathetic and 
sympathetic functions. These tests asses both the resting and reflex 
response in heart rate variability to different challenges. All these tests are 
assigned as recommended by (Task Force) which includes the Resting 
Heart Rate variability. 
The Resting Heart Rate variability is a noninvasive, easy to perform 
and reproduce and are both sensitive as well as specific (Genovelyand et 
al, Pfeifer et al)
13
. An increased HRV indicates the heart’s ability to adapt 
quickly and more flexibly to external and internal influences due to an 
optimally balanced interplay between the sympathetic and parasympathetic 
nervous systems. A decreased HRV indicates a reduced capacity for 
adaptation and may suggest impaired autonomic function and serious health 
impairment. 
The clinical features of hypothyroidism are suggestive of 
sympathovagal imbalance and altered autonomic functions can be improved 
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after attaining euthyroid state with L thyroxine replacement therapy 
(Vijaya Lakshmi et al, N Vaney et al,)
14
. 
Thus our present study proceeds with testing Resting heart rate 
variability on newly diagnosed hypothyroid females and its comparison 
after replacement therapy with L- thyroxine 
Hypothyroidism not only produces sympathovagal imbalance but 
has also been found to be associated structural and functional changes in 
the cardiovascular system and hemodynamics. Some of the 
histopathological changes seen in the hypothyroid cardiomyopathy patients 
include myofibrillar swelling, loss of stratum and interstitial fibrosis 
leading on to pale, dilated, flabby heart with pericardial effusion. These 
changes may produce slowed diastolic relaxation and filling, causing 
diastolic dysfunction. These alterations may lead to decreased systolic 
function in severe disease (Cancuso L et al, Lo Bartolo G et al)
15
. 
These structural and functional changes in hypothyroidism can be 
assessed by Echocardiography which is a very good noninvasive method. 
The various parameters assessed in Echocardiography were myocardial 
wall thickness, cardiac chamber size, left ventricular ejection fraction, 
stroke volume, cardiac output. These changes could be improved after 
treatment with L thyroxine replacement therapy (Jagdish et al, H Singh et 
al)
16
. 
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Therefore in our study, the sympathovagal balance was assessed by 
doing the Resting heart rate variability analysis and assessment of cardiac 
functional status by doing ECHO in the newly diagnosed hypothyroid 
female individuals and compared with normal controls before and after 
treatment with L-thyroxine.   
   
 
  
  
 
 
REVIEW  
OF  
LITERATURE 
  
9 
 
REVIEW OF LITERATURE 
THYROID GLAND - A BRIEF INTRODUCTION 
Thyroid gland is the largest endocrine gland which secretes the 
hormones Thyroxine (T4), Triiodothyronine (T3), and Calcitonin. It is one 
of the first endocrine gland of the body to develop, on approximately the 
24th day of gestation. It is highly vascularized with blood flow at a rate of 
(4-6ml/gram/ minute). The gland is made up of closely packed spherical 
follicles or acini. The follicular epithelium may be cuboidal or columnar in 
type depending upon the activity of gland. Each follicle is filled with 
proteinaceous material called colloid. The other hormone Calcitonin is 
secreted by the para follicular C cells which is concerned with Calcium 
homeostasis. 
The normal human thyroid gland secretes about 80µg (103nmol) of 
T4, 4µg (7 nmol) of T3, 2µg (3.5 nmol) of RT3 per day (Ganong’s Text 
book of Physiology Page no.342 24
th
 edition)
12
. Thyroid hormone 
synthesis is regulated by negative feedback mechanism operating through 
pituitary TSH levels which in turn is influenced by hypothalamic TRH 
levels. 
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Events in Thyroid History 
1915 - Edward Kendall, isolated thyroxine in crystalline form 
1952 - Rosalind Pitt Rivers and Jack Grass discovered triiodothyronine.  
1961 - Calcitonin was discovered 
1988 - gene for beta subunit of TSH was cloned 
1989 - gene for TSH receptor was cloned 
 
Figure 1: Stages of thyroid hormone synthesis 
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Physiologic actions of thyroid hormones 
Thyroid hormones have widespread actions in the body, secondary to 
stimulation of oxygen consumption 
 They have chronotropic, ionotropic effect in the heart by 
increasing the number of ẞ adrenergic receptors, enhanced 
responses to circulating catechol amines, increased proportion 
of α myosin heavy chain with (higher ATPase activity) 
 In adipose tissue- it stimulates lipolysis 
 In Muscles it causes increased protein breakdown 
 In Bones it promotes normal growth and skeletal 
development 
 In Gut it increases the rate of carbohydrate absorption  
 Others include calorigenic effect, increased oxygen 
consumption by metabolically active tissues (except testes, 
uterus, lymph nodes, spleen, anterior  pituitary) and increases 
metabolic rate.  
ACTION OF THYROID HORMONE  ON CARDIAC MYOCYTE. 
Thyroid hormones exert its effect on the heart through 
genomic and non-genomic actions. The genomic actions of 
triiodothyronine (T3) are mediated by high-affinity nuclear receptors 
12 
 
that directly regulate gene expression. But the non-genomic effects 
are rapid and are unaffected by inhibitors of transcription and protein 
synthesis.
 
Figure 2: Mechanism of action of thyroid hormone on cardiac myocyte. 
AC indicates adenylyl cyclase;  -AR, adrenergic receptor; Gs, guanine 
nucleotide binding protein; Kv, voltage-gated potassium channels; NCX, 
sodium calcium exchanger; and PLB, phospholamban. 
GENOMIC ACTIONS: 
The genomic actions of the thyroid hormone are brought by either 
activation of transcription or repression of specific genes that will encode 
the structural and functional proteins (Dillmann, et al, 1990)
17
. After the 
entry of active thyroid hormone T3 directly into the cardiac myocyte, it 
combines with receptors in the nucleus (Everts et al, 1996)
18
. Then it 
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interacts with nuclear receptor α1 (activator) or nuclear receptor α2 
(repressor). On binding with these receptors, along  with recruited 
cofactors,  the  thyroid hormone-receptor complex will bind or release  
some specific sequences of DNA which are known as thyroid responsive 
elements. This in turn will act as cis- or trans-regulators that can alter the r 
transcription speed of specific target genes (Brent et al, 1994)
19
. 
Positively regulated Negatively regulated 
α myosin heavy chain ẞ myosin heavy chain 
Sarcoplasmic reticulum Ca
2+
-
ATPase 
Phospholamban 
Na
+
-K
+
-ATPase 
Adenylyl cyclase catalytic 
subunits 
ẞ1-adrenergic receptor Thyroid hormone receptor α1 
ANP Na
+
-Ca
2
 exchanger 
Voltage gated K
+
 channels   
Table shows Effect of thyroid hormone on cardiac gene expression: 
The proteins that are modulated in the transcriptional level includes 
the myosin heavy chain (Morkin, 1993 et al
20
; Ojamaa et al, 1996
21
 ) and 
calcium activated ATPase that regulates the intracellular calcium and 
phospholamban (Dillmann, 1990; Kiss et al, 1994)
17
.  
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Previous studies done in vitro and in vivo showed that thyroid 
hormone increase the expression of the α myosin heavy chain in cardiac 
myocytes, while it decreases the ẞ isoform (Morkin, 1993 et al20; Ojamaa 
et al, 1996
21
). In humans,The ẞ myosin heavy chain is more pronounced in 
humans than α isoform (Magner J, Clark W, Allenby P 1988)22 and the 
ratio between the two will be modified slightly by thyroid hormone 
(Landenson et al, 1992)
23.
 
Abnormalities of cardiac function in patients with thyroid 
dysfunction directly reflect the effects thyroid hormone on calcium 
activated ATPase and phospholamban. These are involved primarily in the 
regulation of systo diastolic calcium concentrations in cardiac myocytes.  
During diastole the rate of calcium reuptake into the lumen of sarcoplasmic 
reticulum is determined by calcium activated ATPase. This controls the 
velocity of myocardial relaxation after contraction (Dillmann, 1990; Kiss 
et al 1994)
17
.  
The level of phospholamban expression will influence the activity of 
sarcoplasmic reticulum calcium-activated ATPase (Kiss et al, 1994)
24
. It 
has been well demonstrated that the expression of sarcoplasmic reticulum 
calcium activated ATPase is up regulated and expression of 
phospholamban is down regulated (Dillmann, 1990: Kiss et al 1994)
17
. 
The myocardial contractility is increased by calcium reuptake during 
diastole.    
15 
 
The expression of other ion channels such as Na-K ATPase, 
Na+/Ca++ exchanger, voltage –gated K+ channels will help in coordinated 
electrochemical and mechanical responses of the myocardium (Gick et al, 
1990: Ojamaa et al, 1999)
25
.  
The two myosin heavy chains (MHC) present in the heart are alpha-
MHC and beta-MHC, which are encoded by two homologous genes located 
on the short arm of chromosome 17. Each myosin molecule will have two 
heavy chains and two pairs of light chains. The beta-MHC has less ATPase 
activity than the alpha-MHC. Atria has alpha MHC predominantly and on 
treatment with thyroxine its level will be increased thus causing increase in 
the rate of cardiac contraction. But in hypothyroidism, the expression of the 
alpha-MHC gene is depressed and beta-MHC is enhanced. 
NON-GENOMIC EFFECTS: 
This non-genomic actions of the thyroid hormone is more rapid than  
the genomic actions. Acute phosphorylation of phospholamban occurs 
which diminishes the inhibition of phospholamban on calcium -activated 
ATPase in the sarcoplasmic reticulum. This involves the activation of 
intracellular kinase pathways. These are the pathways involved in signal 
transduction of the adrenergic stimulus (Ojamaa et al, 2002)
21
. In this way 
similar in functions of catechol amines and thyroid hormones on the 
cardiovascular system could be explained (Levyandklein,1990)
26
. 
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EFFECT OF THYROID HORMONE ON CARDIOVASCULAR 
HEMODYNAMICS 
Thyroid hormone reduces peripheral vascular resistance by causing 
relaxation in vascular smooth muscle cells (Klemperer et al, 1995: 
Ojamaa et al, 1996; Park et al, 1997)
27
. Thyroid hormones can cause 
extra heat production which leads to a slight rise in body temperature, and 
in turn activate the heat-dissipating mechanisms. Peripheral resistance 
decreased due to cutaneous vasodilation and this increases renal Na+ and 
water absorption, expanding blood volume. Cardiac output is increased by 
direct, as well as due to action of catecholamine on the heart. The pulse 
pressure and heart rate are increased and circulation time is shortened. 
Figure3. Effect of thyroid hormone on cardiovascular hemodynamics 
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RELATION BETWEEN THYROID HORMONES AND CATECHOL 
AMINES: 
The actions of thyroid hormones and catechol amines secreted by 
adrenal medulla are closely interrelated. Adrenaline or Epinephrine also 
increases the rate of metabolism, nervous system excitation and 
cardiovascular actions similar to thyroid hormones. But all these actions are 
very rapid. Nor adrenaline or nor epinephrine is also similar in action 
(Goodman HM, 2000)
28
. In hypothyroidism there is impaired cyclic AMP 
response to epinephrine which suggests decreased responsiveness to 
catecholamine. This reduced responsiveness is associated with all steps of 
catecholamine signaling, including receptor and post receptor actions 
(Larson PR, et al. 2003)
29
. 
T3 may enhance sympathetic nervous system activity by increasing 
the number of β-adrenergic receptors in heart muscle and the generation of 
intracellular second messengers, such as cAMP (Berne and Levy 6
th
 
edition)
30
. Presumably, the functional synergism observed between 
catechol amines and thyroid hormones, particularly in pathological settings, 
arises from their overlapping biological functions as well as the ability of 
thyroid hormones to increase expression of catecholamine receptors and the 
signaling effectors to which they are linked (Ganong et al)
12
. 
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THYROID FUNCTION TESTS 
Laboratory tests can be divided into five major categories: (1) those 
that assess the state of the hypothalamic-pituitary-thyroid axis; (2) 
estimates of the T3 or T4 concentrations in the serum; (3) tests that reflect 
the impact of thyroid hormone on tissues; (4) tests for the presence of 
autoimmune thyroid disease; and (5) tests that provide information about 
thyroidal iodine metabolism.  
Thyroid gland functions can be assessed nowadays by highly 
sensitive and specific hormonal assays. Based on the classic “feedback” 
loop mechanism whereby levothyroxine (T4) and triiodothyronine(T3) 
regulate pituitary synthesis and release of thyrotropin a thyroid-stimulating 
hormone (TSH), it is possible with a highly sensitive TSH assay to 
establish a diagnosis of thyroid disease in essentially every case (Demers 
LM et al, Levey GS, Klien I et al). In patients with overt hypothyroidism, 
the lack of T4 feedback leads to TSH levels -20 mIU/ml, whereas in milder 
or subclinical hypothyroidism the TSH levels are between 3 and 20 mIU/ml 
with normal T4 and T3 levels (Demers LM et al, Surks et al, Oritz I et al). 
Thus the TSH test is the appropriate initial test to screen for thyroid 
dysfunction in a variety of clinical situations known to be affected by 
thyroid disease as well as to confirm a suspected diagnosis and follow the 
response to treatment.  
19 
 
Hormone Normal levels 
TSH 0.4-4.2mIU/ml 
Free T3 0.2-0.5ng/dl 
Free T4 0.7-2.5ng/dl 
Total T3 70-190 ng/dl 
Total T4 5-11µg/dl 
Table shows normal levels of thyroid hormones. (William’s text book of 
Endocrinology)
31
. 
HYPOTHYROIDISM 
Hypothyroidism is the second commonest endocrine disorder next to 
Diabetes mellitus. Hypothyroidism is a clinical state due to reduced thyroid 
hormone levels in circulation. It can be classified as primary 
hypothyroidism due to transient or progressive impairment of thyroid 
hormone biosynthesis. Central or secondary hypothyroidism is due to 
insufficient stimulation of the normal gland due to disease of 
hypothalamus, or pituitary, or due to defects in TSH molecule. 99% of 
hypothyroidism is due to primary causes and less than 1% due to secondary 
causes or TSH defects (William’s Text book of Endocrinology). 
HYPOTHYROIDISM - CLINICAL FEATURES: 
 Easy fatigability, 
 Extreme somnolence 
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 Muscular weakness 
 Delayed ankle jerk 
 Decreased heart rate, decreased cardiac output, decreased blood 
volume 
 Increased body weight, constipation, mental sluggishness, depressed 
growth of hair and dry skin 
 Development of a froglike hoarseness of voice and in severe cases, 
edematous appearance of the body called myxedema. 
CARDIOVASCULAR FEATURES OF HYPOTHYROIDISM 
The decreased thyroid hormone causes are decreased heart rate, mild 
increase in BP, decreased pulse pressure, and mildly increased mean 
arterial pressure, with some amount of exercise impairment (McAllister et 
al, 1995: Klein and Ojamaa, 2000)
32
. 
 Increased QT interval  with inverted or flattened T waves are the 
ECG findings associated with hypothyroidism (Freudlund and Olsson, 
1983: Klein and Ojamaa, 2000)
33
 which shows the prolonged cardiac 
action potential. Due to increased myocardial electrical dispersion in an 
already damaged heart disease these individuals are vulnerable candidates 
for ventricular arrhythmias (Fredlund and Olsson, 1983: Klein and 
Ojamaa, 2000)
33
. 
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 Systemic hypertension is also seen more commonly in patients with 
hypothyroidism (Endo et al
34
,  Saito et al
35
,  Streeten et al,
36
 Klein 1989
37
 
Fletcher and Weetman, 
38
 Fommei and lervasi et al 
39
). The causes for 
increased systemic BP are increased arterial wall stiffness and increased 
peripheral vascular resistance (Dernellis and Panaretou, 2002: Obuobie 
et al 2002)
40
.  
 
TREATMENT OF HYPOTHYROIDISM: 
Hypothyroidism, either primary or central, is gratifying to treat 
because of the ease and completeness with which it responds to thyroid 
hormone. Treatment is nearly always with levothyroxine and the proper use 
of this medication has been reviewed extensively (Roti E, Minelli R, 
Gardini E, et al, Mandel SJ et al, Brent GA et al, Larsen PR et al, Toft 
et al)
41
.  
Hypothyroidism is treated with ease and completeness by 
replacement of thyroid hormone with Levothyroxine (Mandel ST and 
Brent GA et al 1993)
42
. This type of replacement has got an advantage that 
the peripheral deiodination mechanisms will produce the necessary amount 
of T3 in tissues under the normal physiologic control. The principle of 
hormone replacement is to replicate the natural state by providing a 
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prohormone T4 and allowing the peripheral tissues to activate it by 
physiologically regulated mechanisms. 
Levothyroxine has a 7-day half-life. The dose of levothyroxine is 
approximately 1.6 to 1.8 μ g /kg ideal body weight per day. Because of this 
long half –life, missed dose can be taken on the next day. In 
hypothyroidism, this will usually result in normal range of serum TSH 
concentration in 6 weeks. Accordingly, assessments of the adequacy of a 
given dose should be made after 6weeks only. 
To summarize, hypothyroidism may be conceptualized, not just as 
an endocrine disorder affecting all types of tissues of the body but also 
treatable with adequate replacement with L-thyroxine.  
AUTONOMIC NERVOUS SYSTEM 
Langley in 1898 coined the term autonomic nervous system (ANS) as a 
part of the nervous system responsible for homeostasis which innervates all 
organs except for skeletal muscle which is supplied by somatic motor 
system. 
The two major divisions of ANS are sympathetic (thoracolumbar 
division) and parasympathetic (craniosacral division). The two divisions 
work in a coordinated manner to maintain the homeostasis. The enteric 
nervous system in the GIT also forms a part of ANS. The preganglionic 
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and post ganglionic neurons forms the peripheral motor part this nervous 
system.  The axons are small, myelinated, slow conducting B fibers in case 
of preganglionic neurons with more diverging fibers to eight or nine 
postganglionic neurons. This forms a diffuse autonomic output. In case of 
the postganglionic neurons they are mostly unmyelinated C fibers and 
terminate on the visceral effectors (Kandel ER and Schwartz JH, et al )
43
. 
The ratio of preganglionic to postganglionic neurons is smaller (1:15 to 
1:20) in contrast to the sympathetic system.  
This smaller ratio between pre and post ganglionic neurons helps in 
more localized and specified nature of this part of ANS. In contrast, the 
increased ratio of preganglionic and postganglionic neurons correlates with 
wide spread sympathetic autonomic effects and massive sympathetic 
outflow during strenuous physical activity and stressful environments. 
NEUROTRANSMITTERS IN ANS 
The principal neuro transmitter agents involved are acetylcholine in 
the parasympathetic nerve endings and norepinephrine in the  
sympathetic nerve endings. The evidence for this chemical 
neurotransmission was provided by Otto Loewi in 1920 (Ganong et al)
12
. 
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AUTONOMIC INNERVATION OF HEART 
The Heart and the peripheral vascular system are innervated by both 
divisions of ANS. This is controlled by cardiac autonomic centers situated 
in the medulla, which form the integrating centers of cardiac autonomic 
reflex. The sympathetic innervation is controlled by cardiac excitatory area 
in Rostral Ventral Lateral Medulla (RVLM) also known as vasomotor 
center. The cervical sympathetic nerves form the efferent limb of cardiac 
autonomic reflex. The parasympathetic center is located in dorsal motor 
nucleus of vagus and nucleus ambigus and its efferent is the vagus nerve. 
The afferent inputs from various peripheral and central organs reach these 
cardiac autonomic centers. Some inputs excite the cardiac sympathetic 
centers, which in turn inhibits the parasympathetic center. There is an 
antagonistic effect of these both vital centers on each other. 
Distribution of autonomic receptors in heart 
1. Acetylcholine Receptors: The acetylcholine receptors have been divided 
into two types on the basis of their pharmacologic properties. They are 
Muscarinic and Nicotinic cholinergic receptors. Muscarinic type of 
cholinergic receptors is found in heart that is mainly M2 subtype. It is a 
serpentine type of receptor coupled via heterotrimeric G proteins to adenyl 
cyclase. Here the second messenger involved is the cyclic AMP. This 
receptor activation results in decreased production of cyclic AMP which 
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Figure4. Autonomic innervation of Heart 
keeps the potassium channels in the open state and allows K+ efflux to 
occur.  
2. Adrenergic receptors: The adrenergic receptors are divided into two 
types. Most of the postganglionic sympathetic neurons release 
norepinephrine as neurotransmitter which will act through adrenergic 
receptors. Exception to this is sympathetic innervation is sweat glands 
where the postganglionic neurons release acetylcholine and act through 
muscarinic receptors. 
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The adrenergic receptors are G protein coupled receptors and highly 
homologous to the muscarinic receptors. Two major types of adrenergic 
receptors are Alpha and Beta, each of which exists in multiple subtypes 
(e.g., α1, α2, β1, β2 and β3). These receptors activate the intracellular 
signal transduction pathways and acts on membrane channels by increased 
production cyclic AMP as second messenger. The β1 receptors in the heart 
activate the Gs heterotrimeric G protein and stimulate adenylyl cyclase, 
which antagonizes the effects of muscarinic receptors. 
Adrenergic receptor subtypes have a tissue-specific distribution. α1 
receptors predominate on blood vessels, α2 on presynaptic terminals, β1 in 
the heart, β2 in high concentration in the bronchial muscle of the lungs and 
β3 in fat cells. This distribution has permitted the development of many 
clinically useful agents that are selective for different subtypes and tissues. 
MECHANISM OF VAGAL STIMULATION ON HEART:  
The neurotransmitter acetylcholine after release from vagal 
stimulation acts on muscarinic receptors. The permeability of the fiber 
membranes to potassium is increased by opening the special K+ channels. 
This will increase the negativity causing hyperpolarization and makes this 
tissue less excitable. The opening of the Ca+ channels is also slowed.  
 This hyperpolarization will decrease the resting membrane potential 
of the sinus nodal fibers to a more negative level of -65 to -75 mv than the 
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normal level of -55 to -60 mv. So it takes longer time to reach the threshold 
potential for excitation. Therefore vagal stimulation decreases the rate of 
rhythmicity of the SA nodal fibers. 
There may be an absolute reduction in the sinus rate when the vagus 
is stimulated tonically in the presence of sympathetic stimulation. This is 
known as accentuated antagonism. The cardiac response to sympathetic 
stimulation starts immediately and disperses slowly. But the cardiac 
response to vagal stimulation begins after a little latter and dissipates 
quickly. This type of response to vagal stimulation produces rapid dynamic 
beat to beat variation in heart rate and AV conduction in contrast to slow 
temporary response of sympathetic stimulation. 
 When a systolic pressure wave arrives at the baroreceptor sites in 
the carotid and aortic sinus regions the periodic vagal bursting occurs. This 
produces changes in duration of cardiac cycle length in a phasic manner 
allowing the sinus node to discharge at a variable rate that is identical to 
those of vagal burst. In the same manner vagal bursts also prolong AV 
nodal conduction time that is influenced by sympathetic tone.  
A brief vagal burst can decrease the SA node rate without altering 
the AV conduction time. Or it may prolong the AV node conduction time 
but not influencing the sinus node rate.  Because  in a cardiac cycle the 
peak vagal effects can occur at different times. This shows that vagus can 
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have both direct and indirect effect by altering the sympathetic influences 
(Levy MN et al, 1994)
11
.  
MECHANISM OF SYMPATHETIC STIMULATION ON HEART: 
Stimulation of sympathetic nerve releases the neurotransmitter 
adrenaline at its nerve endings which acts on ẞ1 receptors causing rapid 
opening of Ca+ channels. Accelerating the rate of depolarization and slope 
of the  prepotential increases the heart rate. The rate of impulse formation 
in the SA node is increased by stimulation of right stellate ganglion. The 
rate of conduction in the AV node is increased by left stellate ganglion. 
Acetylcholine increases the refractory period and Norepinephrine 
decreases the refractory period in the center of sinus node. Acetylcholine 
binds with the M2 receptors in the sinus node. After binding a specific G1 
protein is stimulated. This in turn activates the K channel and will modulate 
the discharge rate. Inhibition of adenylate cyclase via G1 also antagonizes 
the adrenergic effects on the sinus node. After the end of vagal stimulation, 
sinus node discharge rate may automatically accelerate transiently which 
causes post vagal tachycardia (Bouman LN et al, 1978)
44
. 
CENTRAL CONTROL OF AUTONOMIC FUNCTION: 
Higher centers comprising of hypothalamus, brainstem, limbic 
system have vital connections with the preganglionic neurons to integrate 
and regulate internal visceral functions to maintain homeostasis. 
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Because of the major role of the hypothalamus in autonomic 
function, it has at times been labeled as the “Head ganglion of the ANS.” 
The sensory and motor areas  involved in control of autonomic function 
includes the insular and medial prefrontal areas of the cerebral cortex. The 
autonomic components of emotional responses are regulated by amygdala 
in the temporal cortex. The areas of the cerebral hemispheres, 
diencephalon, brainstem and central pathways to the spinal cord that are 
involved in the control of autonomic functions are collectively termed the 
central autonomic network. 
AUTONOMIC DYSFUNCTION IN HYPOTHYROIDISM 
There are several studies reflecting the role of ANS in 
hypothyroidism some showing sympathetic activity and others showing 
parasympathetic activity.  
Inukai et al 
45
 on evaluated the parasympathetic nervous activity in 
hypothyroid individuals by determining the RR interval variations on 
Electrocardiogram. He observed a reduction in RR interval variations in 
patients with primary hypothyroidism. There are also decreased 
parasympathetic activities with reduced levels of thyroid hormones. 
Also he observed the Power spectral analysis of hypothyroid patients 
with Hashimoto’s thyroiditis showed decreased LF/HF ratio than the  
healthy subjects. 
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Kahaly et al (2000)
46
 observed in his study on cardiovascular system 
and  atherogenic aspects of subclinical hypothyroidism that decreased Heart 
Rate Variability can be appreciated in subclinical hypothyroidism even 
with little changes in the levels of thyroid hormones. He also reported that 
RR interval variations were restored to normal after treatment. 
Matsukawa et al (1993)
47
, observed the change in muscle sympathetic 
nerve activity in thyroid disorders. He observed that there may be a positive 
correlation of TSH and muscle sympathetic nerve activity. This denotes an 
inverse relationship between thyroid gland function and sympathetic nerve 
activity. 
Momose et al (1997)
48
 demonstrated that increased cardiac as well as 
generalized sympathetic activity in hypothyroid individuals by using 
Iodine-123 metaiodobenzylguanidine scintigraphy.  
Guasti et al
49
 suggested that there may be differences in local 
concentrations of NE or altered post-receptor signaling in patients with 
thyroid dysfunction. He observed that after treatment there was a reduced 
sympathetic activity in hypothyroid patients. 
Fommei et al (2002)
50
 in his study on role of thyroid hormone on 
blood pressure homeostasis found that decreased thyroid hormones may 
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cause an increase in BP as well as excitation of sympathetic system. This 
increased BP was seen to be reducible with thyroid hormone replacement.  
Galetta et al (2008)
51
 on evaluating the subclinical hypothyroid 
patients with heart rate variability and QT dispersion observed a decrease in 
sympathovagal modulation of heart rate with an increased QT intervals. 
Cacciatori V, Gemma ML, et al (2000)
52
 observed lowered total 
power in hypothyroid patients on HRV analysis of heart rate in 
hypothyroidism. 
Sahin I, Turan N, Kosar F et al (2005)
53
 evaluated autonomic 
balancey in subclinical hypothyroid patients and observed significantly 
lowered total power in untreated subclinical hypothyroid individuals. 
Xing H et al (2001)
54
 showed significantly lower values of HF power 
and HF norm in untreated hypothyroidism indicating their reduced vagal 
modulation of heart compared to euthyroid and treated hypothyroid patients 
who obtained euthyroid  status.   
Bhat AN et al
55
 found increased sympathetic activity in hypothyroid 
compared to normal controls in their study. 
Coulombe P et al (1976)
56
 by studying the secretion rate of 
epinephrine in thyroid disorders found that increased sympathetic activity 
and decreased vagal modulation can occur in hypothyroidism. But 
32 
 
bradycardia seen in  hypothyroidism may be due to receptor 
desensitization. Also there may be decreased chronotropic response to 
inspite of increased sympathetic activity. 
Polikar R et al, Kennedy B et al, Maisel A et al, Ziegler M et al 
(1990)
57
 in their study also observed the similar findings as above in 
hypothyroidism. 
Ahmed M, Begum N, Ferdousi S, et al, (2010)
58
 found alteration in 
cardiac autonomic activity characterized by decreased vagal activity and 
increased sympathetic activity in hypothyroidism by doing power spectral 
analysis.   
Manhem P, Bramnert M, Hallengren B et al (1992)
59
 showed raised 
plasma levels of catechol amines in hypothyroidism with decreased 
adrenergic responses at cardiac and peripheral level. This may indicate pre 
and post receptor desensitization. 
Heemstra KA et al, Burggraaf J et al, Vander Klaauw AA et al
60
 
observed metabolic actions of thyroid hormone. There may be an increased 
protein deposition in extracellular space causing increased water content in 
myocardial wall. There is fibrosis which will lead to increased 
inhomogeneity of ventricular repolarization. Moreover they also observed 
opposing effects on circulating lipids, swelling of vascular smooth muscle 
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and altered endothelial cell function in their study involving the effect of 
short term overt hypothyroidism on sympathovagal balance in 
thyroidectomy done patients of differentiated thyroid carcinoma.    
Akcakoyun M, Emiroglu Y, Pala S, et al (2010)
61
 also reported a 
hypo functional parasympathetic system based on analysis of heart rate 
recovery and RR variations in ECG in patients of subclinical 
hypothyroidism. 
Luboshitzky R, Aviv A, Herer P, Lavie Let al (2002)
62
 on analyzing 
the various complicating factors for heart disease in women with 
subclinical hypothyroidism observed raised diastolic blood pressure in 
these individuals. 
 The current study proceeds with studying the autonomic system 
functioning in hypothyroid females before and after therapy with L-
thyroxine.  
HEART RATE VARIABILITY: 
Heart rate variability refers to the beat - to - beat variation in 
heartbeat. Even in a healthy individual, the resting heart beat is not strictly 
regular, an observation described by Albrecht Von Haller in the 18
th
 
century. The duration of cardiac cycle varies from beat to beat and this 
spontaneous variation of RR interval in milliseconds from beat to beat is 
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known as Heart rate variability. Intrinsic automaticity of the sinoatrial node 
and modulating influence of the autonomic nervous system determines the 
rate and rhythm of heart. Under resting conditions, the vagal or 
parasympathetic tone predominates. 
. The variations in heart rate are largely dependent on vagal 
modulation, which releases acetylcholine on stimulation. There will be 
release of epinephrine or norepinephrine on stimulation of sympathetic 
nerves in the heart (levy MN et al, 1971)
63
. Heart rate variability is the 
conventional term used to describe variation of both instantaneous heart 
rate and R-R intervals. The other terms used to describe are cycle length 
variability, heart period variability, R-R interval tachogram, R-R 
variability. This more precisely explains that this interval is between two 
successive heart beats rather than the heart rate.  
The physiological basis for this heart rate variability originates from 
fluctuations in the cardiovascular vasoconstrictor and vasodilator centers in 
the brain. These fluctuations usually arise due to baroreflex mediated 
changes in blood pressure, respiration, thermoregulation and circadian 
rhythm. All these oscillators will have an influence over the length of RR 
interval. 
The balance between the sympathetic and parasympathetic system is 
constantly changing to achieve optimum in response to various internal and 
external stimuli and to maintain the homeostasis. The increased HRV 
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indicates the more flexible and quicker response of the heart to various 
internal and external influences. Decreased HRV reflects the dysfunction of 
autonomic nervous system as well as low HRV may indicate a reduced 
capacity for adaptation and may suggest health impairment (Sampson MB,  
Mudaliar NA, Lele AS; 1980)
64
.  
With normal accepted range of other physiological parameters, HRV 
can reflect changes in body stress. Some HRV changes might be a first sign 
of distress, reflecting involvement of energy more dependent sympathetic 
system. The decrease in biological signals variability is a warning sign of 
loss of self-regulating   homeo kinetic  mechanisms. 
 Heart rate variability (HRV) is a measure of the respiratory sinus 
arrhythmia in which the heart rate accelerates during inspiration, and 
decelerates during expiration, in which the R-R interval in an ECG is 
shortened during inspiration and prolonged during expiration and is due to 
oscillations in sympathetic nerve discharge synchronized with respiratory 
rhythm. This is a normal phenomenon, which may decrease with age and 
also under stressful conditions. 
 Animal studies have shown that HRV is considered as a marker of 
vagal activity (Brouha and Nowak, 1939)
65
. This can be evidenced in 
humans by blocking the parasympathetic system by atropine (Bernston et 
al, 1994)
66
 which indicates that HRV is a function of parasympathetic 
activity. 
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The clinical relevance of HRV was first appreciated by noting the 
fact  that fetal distress was preceded by alterations in inter beat intervals 
before any appreciable change occurred in heart rate itself (Hon and Lee et 
al; 1965)
67
.  Attention was focused on the existence of physiological 
rhythms imbedded in the beat-to-beat heart rate signal by Sayers and others 
to detect the autonomic dysfunction in diabetic patients. Ewing et al
68
 
described some simple bedside tests of short-term HRV. The increased risk 
of relation between post infarction mortality and reduced HRV was first 
observed by (Wolf et al; 1977)
69
. Power spectral analysis of heart rate 
fluctuations was introduced by (Akselrod et al; 1981)
70
.  
Stein P.K. et al (1994)
71
 recommended that the activity of 
sympathetic and parasympathetic innervation on sinus node of heart can be 
measured with heart rate variability as it is a non-invasive cardio graphic 
marker.  
 Among the various tests, the resting Heart rate variability can be 
used as the noninvasive test to evaluate the sympathovagal balance at 
sinoatrial node and functional state of ANS (Juan Sztajzel et al, 2004)
72
. 
  In last 30 years various studies were conducted which showed the 
relationship between autonomic nervous system activity (ANS) and sudden 
death in cardiac arrhythmias (Levy et al, 1994)
73
. 
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COMPONENTS OF HEART RATE VARIABILITY: 
During resting state vagal tone is predominant and variation in heart 
period is mostly dependent on vagal modulation. Vagal and sympathetic 
activity constantly interacts with each other. The R-R interval variation 
present during rest represents a control mechanism which finely tunes the 
heart rate from beat to beat. Afferent vagal stimulation results in efferent 
vagal activity and inhibition of sympathetic activity.  
The opposite reflex occurs by stimulation of afferent sympathetic 
activity. The efferent vagal activity appears to be under “tonic” restraint by 
cardiac sympathetic activity. Efferent sympathetic and vagal activity 
directed to the sinus node and characteristic discharge from it, is largely 
synchronizing with each cardiac cycle. And it can be modulated by central 
(vasomotor and respiratory center) and peripheral (arterial pressure and 
respiratory movements) oscillators.  
These oscillators generate rhythmic fluctuations in efferent neural 
discharge that manifest as short and long term oscillations in heart period.  
(Task Force 96)
74
. Analysis of the rhythm would reveal as about the  
1) Central oscillatos 
2) Sympathetic and efferent vagal activity  
3) Humoral factor  
4) Sinus node activity.  
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CLINICAL USES OF HRV: 
 HRV is the non‐invasive simple test for measuring both 
cardiovascular and non-cardiovascular autonomic function. 
 To evaluate the treatment effectiveness and prognosis 
 HRV is used for exercise training in sports physiology 
 To assess the effect of various stress relaxation programs like 
massage, exercise, meditation, yoga 
 HRV analysis is a predictor of risk after MI, arrhythmias 
 Can be used to find out autonomic dysfunction in diabetes mellitus 
patients. 
 
Conny MA et al
75
 suggested the two types of heart rate variability 
assessment: 
1. Time domain methods – the various indices were calculated by statistical 
methods on RR intervals. 
2. Frequency domain methods - by spectral analysis of RR intervals. The 
accurate timing of R waves is must in both these methods. The analysis can 
be done both on short term ECG segments which will last for 0.5-5 minutes 
or on 24 hour ECG recordings. Rapid changes in heart rate is indicated by 
short-term variability (STV) indices. 
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In HRV analysis either the heart rate as a function of time or the 
intervals between successive QRS complexes need to be determined. In this 
review the term HRV actually means the variability of RR intervals (i.e. 
intervals between consecutive R peaks). We get RR intervals through ECG 
in milliseconds. By using the specific software algorithms the recorded 
ECG signal can be processed in such way that the regular heart beat pattern 
can be determined. 
 
Figure 5: Variability of RR Interval. 
R-R interval: The duration of time between two subsequent R wave peaks 
is called as the R-R interval. The duration of the RR interval is determined 
by the combined effect of sympathetic and parasympathetic tones. If a 
particular RR interval becomes longer than preceding one, it indicates a 
relative increase in vagal tone compared to the sympathetic tone during that 
period. Similarly increase in sympathetic tone or decrease in 
parasympathetic tone is reflected as reduced RR interval or an increased 
heart rate (Philip A. Low 1997). It is usually expressed in seconds or 
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milliseconds. Among the limb leads, the R-R interval obtained in ECG 
recording of lead II is specific.  
The two methods used to measure heart rate variability on the basis 
of R-R interval fluctuations are 
 Time domain methods 
 Frequency domain methods 
TIME DOMAIN METHODS: 
The time domain methods are simplest to perform since they are 
applied straight to the series of successive RR interval values. 
By a continuous ECG record, the heart rate at any given point in time or the 
interval between two successive normal complexes is determined. Different 
variables measured includes 
 
Variable Units Description 
Statistical Measures 
SDNN ms Standard deviation of all NN intervals 
SDANN ms 
Standard deviation with respect to the 
averages NN intervals in all 5-minute 
segments for the entire recording 
RMSSD ms Square root of the mean of the sum of the 
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squares of differences between adjacent NN 
intervals 
SDNN index ms 
Mean of the SD of all NN intervals of all 5-
minute segments for the entire recording 
SDSD ms 
Standard deviation of differences between 
adjacent NN intervals 
NN50 count 
 
Number of pairs of adjacent NN intervals 
differing by more than 50 ms in the entire 
recording; three variants are possible counting 
all such NN intervals pairs or only pairs in 
which the first or the second interval is longer  
pNN50 % 
NN50 count divided by the total number of all 
NN intervals 
 
Every QRS complex is recorded and NN interval (complete intervals 
among contiguous QRS complex is determined. 
Other commonly used variables are Mean HR, Mean RR. 
FREQUENCY DOMAIN METHODS 
In this method, for the RR intervals, a power spectrum density (PSD) 
estimate is calculated. Then the RR interval series is changed to uniformly 
distributed or distanced sampled series by interpolation methods prior to 
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PSD estimation. FFT based methods or parametric AR modeling based 
methods are usually used for PSD estimation. FFT based methods have the 
merits due to the simplicity of implementation, though the AR spectrum 
yields improved resolution particularly on lesser samples size. 
 
 
 
Variable Units Description Frequency 
Range 
Analysis of Short-term Recordings (5 min) 
5-min total 
power 
ms
2
 The variance of NN intervals over 
the temporal segment 
≈≤0.4 Hz 
VLF ms
2
 Power in VLF range ≤0.04 Hz 
LF ms
2
 Power in LF range 0.04-0.15 Hz 
LF norm Nu LF power in normalized units 
LF/(total power−VLF)×100 
 
HF ms
2
 Power in HF range 0.15-0.4 Hz 
HF norm Nu HF power in normalized units 
HF/(total power−VLF)×100 
 
LF/HF  Ratio LF [ms
2
]/HF[ms
2
]  
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VLF (0-0.04Hz): 
Primarily indicates sympathetic activity, renin angiotensin system 
activity, baroreflex activity and thermo regulation. 
Not relevant in 5min ECG recordings. 
LF power (0.04-0.15Hz) 
LF shows baroreflex mediated blood pressure maintenance of the 
sympathetic system. 
This is an indicator for more sympathetic than parasympathetic 
modulation. This needs minimum of 2 minutes ECG recording. 
HF power (0.15-0.4Hz): 
HF power reflects parasympathetic activity mainly like gas exchange 
efficiency and RSA, which are mediated by vagus nerve. 
Even 1 minute ECG recording is enough 
 
ULF- less than 0.003 Hz 
Mainly used for analyzing long term recordings (24 h), becomes 
relevant clinical significance is not clearly defined. 
The standard deviation of the mean RR interval is a commonly 
determined cardiovascular autonomic function. The standard deviation 
provides a statistical measure of the variability or spread of the RR intervals 
around the average heart rate. The results of this determination depend on 
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the number of observations (RR intervals) and the mean Heart rate (Smith 
SE and Smith SA et al, 1981)
76
. 
It is proposed that a measure based on successive differences in the 
RR intervals, that are the actual difference between adjacent RR intervals 
would be more sensitive than the standard deviation to short term 
fluctuations in heart rate. The mean square successive difference (MSSD) is 
the average of the square of the differences between successive beats; the 
RMSSD is its square root (Gundersen and Neubauer et al, 1981)
77
 
In this study we are using both Time domain and Frequency domain 
methods of resting heart rate variability analysis to determine the 
sympathovagal balance in hypothyroid female subjects and the changes 
observed with L-thyroxine therapy. 
ECHOCARDIOGRAPHY IN HYPOTHYROIDISM 
Cardiovascular imaging with Echocardiography plays an important 
role in evaluating structural and functional status of the heart. The Two-
dimensional (2D) echocardiography helps to view the heart directly with 
ultra-sonogram. This gives on the spot assessment of the myocardium, 
chambers, heart valves, vessels and pericardium. Doppler study gives the 
velocity of moving red blood cells. This can be used to assess of 
hemodynamics non invasively replacing cardiac catheterisation.  
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The principle behind 2D echocardiography is reflection of ultrasonic 
waves from cardiac structures that produces images of the heart for a 
transthoracic echocardiogram (TTE). Recent ECHO machines are portable. 
So the key merits of echocardiography over other modalities are the 
capability in obtaining instantaneous images of the heart structures for swift 
interpretation.  
A constraint of TTE is the difficulty in obtaining better-quality 
images of patients with a thick chest wall or severe lung disease, due to the  
poorly transmission of ultrasound waves through lung parenchyma. 2D 
echocardiography is also the perfect imaging modality for analysing left 
ventricular (LV) size and function. A qualitative assessment of the 
ventricular cavity and systolic function can be made directly from the 2D 
image. LV hypertrophy and hypertrophic cardiomyopathy can be diagnosed 
with 2D echocardiography. Others like left atrium and right champers 
assessed by visual analysis. 
Cardiovascular disorders associated with hypothyroidism include 
decrease in myocardial contractility, pericardial effusion, and increase in 
left ventricular mass and prolonged duration of contraction and relaxation. 
The ejection fraction, cardiac reserve are slightly diminished (Stiefelhagen 
P et al 2009)
78
 The various clinical studies on cardiac involvement in 
subclinical hypothyroidism consistently shows that patients exhibit resting 
left ventricular diastolic function evidenced by delayed relaxation, and 
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impaired systolic function on effort that results in poor exercise capacity 
(Rodondi N et al, (2007), Aujesky D et al, Vittinghoff E et al 2006)
79
. 
Most of these cardiac manifestations are reversible with timely and 
adequate therapy. 
The various echocardiographic parameters that are assessed includes 
left ventricular posterior wall thickness(LVPW),  Interventricular 
septum(IVS), Ejection fraction(EF%)-for LV systolic function, cardiac 
chamber size mainly LVID –left ventricular internal diameter both end 
systolic(ES) and end diastolic(ED). 
As a non –invasive method, echocardiography can play an important 
role in recognizing the cardiac pathology as well as to follow up effect in 
the therapy. 
There is alteration of myocardial wall thickness in hypothyroidism 
as shown by various studies. Bennet et al (1983), Lee et al (1990)
80
, 
Bernstein et al (1995)
81
 reported considerable increase in incidence of 
asymmetrical septal or concentric hypertrophy in these patients. The cause 
increased wall thickness in hypothyroidism could be due to altered 
peripheral vascular resistance in these patients. 
There are also decreased systolic functions in hypothyroidism as 
observed by Forfar et al (1992)
82
. The cause for reduced cardiac output 
may be decreased stroke volume and heartrate. The decreased cardiac index 
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in hypothyroidism could be reversed with thyroid hormone replacement as 
per Kral et al (1992)
83
. 
This study uses the Echocardiographic parameters like ejection 
fraction and LVID as a measure of functional state of the heart in normal 
and hypothyroid females before and after treatment with L–thyroxine 
replacement therapy. 
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AIM AND OBJECTIVE OF THE STUDY 
 
AIM OF THE STUDY 
             To assess the Resting Heart Rate Variability and Echocardiography 
in normal and hypothyroid (female) patients before and after treatment.  
OBJECTIVES OF THE STUDY 
              1. To analyze the Resting Heart Rate Variability in newly 
diagnosed hypothyroid (female) individuals   before treatment and normal 
healthy females. 
             2. To assess the cardiac functional status by doing 
Echocardiography in newly diagnosed hypothyroid (female) individuals 
before treatment and normal healthy females. 
             3. To compare the changes in Heart Rate variability and 
Echocardiography before and after treatment with thyroxine in hypothyroid 
female individuals.    
 
 
  
  
 
 
 
 
 
MATERIALS AND 
METHODS 
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MATERIALS AND METHODOLOGY 
This study was conducted in the Institute of Physiology and 
Experimental Medicine, Madras Medical College, Chennai in association 
with the Medical Endocrinology Outpatient Department, Rajiv Gandhi 
Government General Hospital, Chennai, after obtaining the ethical 
committee clearance. 
The study was conducted in the period of September 2014 to August 
2015. 
The study group consists of 30 female subjects who were newly 
diagnosed hypothyroid individuals in the age group 20-35 years. The 
control group includes of 30 age matched, euthyroid females for 
comparison with the cases. 
The subjects were informed about the  study details,  procedures and 
their acceptance to participate in the study was obtained as written consent  
from them.  
INCLUSION CRITERIA 
Newly diagnosed hypothyroid females with estimated (serum TSH 
levels above 10mIU-100mIU/ml with both normal and decreased serum T3 , 
T4 levels) in the age group of 20-35 years are included in this study as 
cases. 
For the purpose of statistical analysis, the study subjects are 
considered as following groups:  
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Group A : Normal control  
Group BBT : Hypothyroid ( newly diagnosed cases, before starting  
treatment) 
Group BAT : Hypothyroid (after treatment with L-thyroxine for minimum 
3months and who have attained euthyroid status with therapy) 
 
EXCLUSION CRITERIA 
Pregnant females, subjects taking oral contraceptives or drugs 
affecting heart rate, subjects with anemia (Hb less than 10gm/dl), 
hypertension, diabetes mellitus, underlying known respiratory, cardiac, 
renal, hepatic, neoplastic conditions, and other concurrent medical illness 
are excluded from the study.   
MATERIALS 
 Niviqure ambulatory digital ECG recorder (INCO) 
 Sphygmomanometer 
 Stethoscope 
 Philips HD 7 Diagnostic ultra sonographic machine (2D ECHO) 
Estimation of serum T3, T4, TSH levels: 
Serum analysis of T3, T4, TSH levels were done in Biochemistry 
Laboratory at Rajiv Gandhi Government Hospital. The T3, T4, TSH levels 
are measured using ELISA method. As a parameter for statistical analysis 
the serum TSH levels only taken. 
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HRV ANALYSIS 
Niviqure Ambulatory Digital ECG recorder 
Niviqure is a solid state, multi load, digital, standalone computerized 
recording system designed to acquire, analyze and ECG data over long 
period. This data is acquired and stored in flash memory for later 
 down loading and analysis. The data transfer from memory module and 
computer is through an interface Rs233C, compatible module.  
 Niviqure has powerful processing software for online ECG study, 
data storage, off line data replay and study and data transfer to other 
software for statistical analysis and FFT analysis. 
Flow chart given below shows the basic steps used to record and 
process the ECG  signal  to obtain data for HRV analysis.  
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METHODOLOGY 
 The subjects were asked to fill a proforma to assess the general 
status and clinical symptoms suggestive of hypothyroidism. 
 After getting an informed and written consent from the subjects, general 
and systemic examination were carried out and height in meters and weight 
in kilograms were also measured. 
 Body mass index (BMI) was calculated using the formula 
weight/height in m². The short term Resting HRV analysis for 5 minutes 
was recorded in the subjects.  
 
 
Short term HRV analysis 
 As per the recommendations of the Task force of the European 
Society of Cardiology and the North-American Society of Pacing and 
Electrophysiology in 1996, the short term HRV recording was done for 5 
minutes. 
Pretest instructions were given to the subjects as below: 
 The subjects were advised to have a good sleep at night before the 
examination day. 
 No heavy activity 24 hours prior to recording. 
 Advised to avoid tea, coffee like drinks on the day of testing 
 Mobile phones must be switched off 
53 
 
 The subjects were asked to empty the bladder before the test 
 The subjects should be relaxed, comfortable and free from recent 
acute illness, and without significant anxiety. 
 
The test should be performed in a quiet room with lighting sub duded, 
temperature controlled and sound proofed, well electrified room.  
The subject was made to rest quietly in supine position in a cool and calm 
environment, for a minimum period of twenty minutes. 
 Electrodes were placed in the following positions after cleaning the 
site with spirit cotton and connecting the channels to transducer for ECG 
with computer the HRV was recorded. 
EXPLORING ELECTRODE RIGHT SHOULDER 
EXPLORING ELECTRODE LEFT SHOULDER 
EXPLORING ELECTRODE LEFT SUBCOSTAL 
REFERENCE ELECTRODE RIGHT SUBCOSTAL 
 
The rest period was increased to 30 minutes and then ECG was 
acquired by continuous ECG recording for five minutes (320 seconds) 
which is needed for short term HRV analysis. After screening for the 
artefact and editing it, the results were fed to HRV analysis software 
(Kubios). 
1. Niviqure Digital ECG system 
 
 
 
2. Resting HRV Analysis 1 
 
 
  
3. Resting HRV Analysis 2 
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 The analogue to the digital conversion of the resting ECG signal 
was done using AD converter with sampling frequency of 1024/sec. Power 
spectral analysis of the converted ECG signal was done using Fast Fourier 
Transformation. 
Mean RR, standard RR, Mean HR, standard HR, SDNN, RMSSD, 
Low Frequency, High Frequency, LF/HF ratio, Total power were 
estimated. 
 
ECHOCARDIOGRAPHY 
Echocardiography measurements were performed using 2 
dimensional mode, Philips HD 7 diagnostic ultra sonographic machine in 
the Department of Cardiology. As a parameter of systolic function we 
measured the left ventricular ejection fraction. Normal reference range of 
ejection fraction is ≥ 55%. The left ventricular internal diameter (end 
diastolic) of 3.9-5.3 cm is taken as the normal reference range in women. 
(Harrison’s  principles of Internal Medicine, 18th Edition). 
 Other parameter assessed is the presence of absence of pericardial 
effusion. After measuring all these parameters the study subjects were 
advised treatment with L-thyroxine in a minimum dose of 25µg up to 
100µg/day according to the serum TSH levels. 
 At the end of 3 months of treatment serum TSH levels are again 
measured and after attaining the normal serum TSH levels or euthyroid 
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state, the short term HRV analysis and Echocardiographic measurements 
were taken again. 
By using the same methodology, the above said estimation of serum 
TSH, Short term HRV analysis, Echocardiographic measurements were 
done in the normal controls. Then the study group (newly diagnosed 
hypothyroid) were started on L-thyroxine therapy for 3 months at a dose of 
minimum 12.5µg-100µg once daily according to the serum TSH estimation.  
After 3 months of therapy serum TSH levels are estimated and after 
attaining normal euthyroid levels, the short term Resting Heart rate 
variability analysis and Echocardiography were repeated. The results were 
analyzed for both the controls and study group before and after therapy. 
Statistical analyses of the data were done using paired and unpaired t tests. 
  
  
 
 
 
 
RESULTS 
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RESULTS 
The statistical analysis of the data obtained from conducting the 
Heart Rate Variability analysis and Echocardiographic study in normal and 
hypothyroid female individuals before therapy and after attaining euthyroid 
status with L thyroxine were done using the Statistical Package for the 
Social Sciences (SPSS) software version 21. The Mean and Standard 
deviation of the variables were determined for the three groups namely 
Group A, Group BBT , Group AAT. The unpaired’t test was done between 
normal and hypothyroid female individuals before starting therapy with L 
thyroxine. And ‘paired’t test was done among hypothyroid female 
individuals before and after therapy with L thyroxine. Both tests were 
employed as the Test of significance at 95% confidence interval. P value 
<0.05 was considered as significant. 
In the following section, the 3 groups of study subjects will be referred 
to as follows:  
Group A : Normal control  
Group BBT : Hypothyroid (newly diagnosed cases, before starting  
treatment) 
Group BAT : Hypothyroid (after treatment with L-thyroxine for minimum 
3months and who have attained euthyroid status with therapy) 
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TABLE-I 
Comparison of BMI among normal and hypothyroid individuals 
(before therapy) 
 
  P value *- significant  **- highly significant  ***- very highly significant 
 
TABLE- I compares the BMI among normal and hypothyroid individuals 
before therapy with L-thyroxine. This was very highly significant.   
Study groups N Mean ±  SD P value 
Group A 30 23.62 ± 1.12 
0.000*** 
Group BBT 30 25.97 ± 1.37 
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TABLE-II 
Comparison of resting parameters among study groups 
 
* - significant   **- highly  significant  ***- very highly significant  
 
Parameters Study groups N Mean  ±  SD P value 
Resting 
HR/min  
Group A 30 77.73 ± 2.89 
0.000*** 
Group BBT 30 72.30 ± 5.97 
Group BBT 30 72.30 ± 5.97 
0.004* 
Group BAT 30 77.66 ± 8.12 
Resting  
SBP/mmHg 
Group A 30 117.00 ± 5.68 
    0.085 
Group BBT 30 119.80 ± 6.69 
Group BBT 30 119.80 ± 6.69 
    0.613 
Group BAT 30 119.00 ± 7.34 
Resting  
DBP/mmHg 
Group A 30 74.80 ± 3.39 
0.003* 
Group BBT 30 77.87 ± 4.23 
Group BBT 30 77.87 ± 4.23 
0.006* 
Group BAT 30 75.00 ± 3.43 
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TABLE- II compares the Resting HR/min, Resting SBP and Resting 
DBP among the study groups. The mean value for Resting Heart rate in 
normal and hypothyroid individuals before therapy was highly significant. 
The mean value of Resting HR in hypothyroid individuals before and after 
therapy was significant. 
The mean value or Resting SBP among study groups was not 
significant. The mean value for Resting DBP in normal and hypothyroid 
individuals before therapy and after L- thyroxine therapy was significant. 
  
Graph 1: Comparison of resting parameters among 
study groups 
1a.Resting Heart Rate/min 
 
1b.Resting SBP (mmHg) 
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TABLE-III 
Comparison of Serum TSH in mIU/ml, among study groups 
 
***- very highly significant 
 
TABLE-III shows the comparison of serum TSH levels among study 
groups. The mean value of serum TSH levels between normal and 
hypothyroid individuals before treatment was very highly significant. And 
the mean value of serum TSH levels among hypothyroid individuals before 
and after L-thyroxine therapy was also very highly significant. 
  
Study groups N Mean ±  SD P value 
Group A 30 3.30 ± 1.01 
0.000*** 
Group BBT 30 29.42 ± 12.50 
Group BBT 30 29.42 ± 12.50 
0.000*** 
Group BAT 30 4.22 ± 0.96 
Graph.2. Comparison of Serum TSH (mIU/ml) levels 
among study groups 
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TABLE-IV Comparison of ECHO parameters among study groups 
 
***- very highly significant 
 
 
Parameters Study groups N Mean  ±  SD P value 
Ejection 
Fraction in 
%age 
Group A 30 59.70 ± 2.96 
0.000*** 
Group BBT 30 49.67 ± 2.95 
Group BBT 30 49.67 ± 2.95 
0.000*** 
Group BAT 30 58.36 ± 3.69 
LVID (End 
Systolic) in 
cms 
Group A 30 2.78 ± 0.19 
0.000*** 
Group BBT 30 3.81 ± 0.23 
Group BBT 30 3.81 ± 0.23 
0.000*** 
Group BAT 30 2.67 ± 0.23 
LVID (End 
Diastolic) 
in cms 
Group A 30 4.56 ± 0.26 
0.000*** 
Group BBT 30 4.97 ± 0.31 
Group BBT 30 4.97 ± 0.31 
0.000*** 
Group BAT 30 4.52 ± 0.25 
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TABLE-IV shows the comparison of ECHO parameters among 
study groups. The mean value of Ejection fraction between normal and 
hypothyroid individuals before treatment was very highly significant. And 
the mean value of Ejection fraction among hypothyroid individuals before 
and after L-thyroxine therapy was also very highly significant. 
 The mean value of Left Ventricular Internal Diameter (End systolic) 
between normal and hypothyroid individuals before treatment as well as 
after therapy was very highly significant. 
The mean value of LVID (End diastolic) between normal and 
hypothyroid individuals before treatment as well as after therapy was very 
highly significant.  
Graph3. Comparison of ECHO parameters among 
study groups 
3a. Ejection fraction (%) 
 
 
3b. LVID (cm)- End Systolic 
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3c. LVID (cm) – End Diastolic 
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TABLE-V Comparison of Time Domain measures of HRV 
Parameters Study groups N Mean  ±  SD P value 
Mean Heart 
Rate/min 
Group A 30 79.20 ± 5.96 
0.000*** 
Group BBT 30 72.40 ± 6.64 
Group BBT 30 72.40 ± 6.64 
0.002* 
Group BAT 30 78.50 ± 8.90 
Mean RR 
interval in 
ms 
Group A 30 807.17 ±124.49 
0.0236* 
Group BBT 30 869.03 ± 75.89 
Group BBT 30 869.03 ±75.89 
0.794 
Group BAT 30 800.43 ±94.09 
SDNN(ms) 
Group A 30 44.37 ± 8.36 
0.002* 
Group BBT 30 37.53 ± 4.69 
Group BBT 30 37.53 ± 4.69 
0.202 
Group BAT 30 36.99 ± 4.74 
RMSSD(ms) 
Group A 30 35.17 ± 6.86 
0.545 
Group BBT 30 33.76 ± 10.60 
Group BBT 30 33.76 ± 10.60 
0.259 
Group BAT 30 34.74 ± 8.67 
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TABLE-V shows comparison of Time domain measures of Resting 
HRV among study groups. The mean value of Mean HR/min among the 
normal and hypothyroid individuals before therapy was highly significant. 
The mean value of Mean RR between normal and hypothyroid individuals 
before therapy was significant. 
 The mean value of SDNN between normal and hypothyroid 
individuals before therapy was significant.  
 The mean RMSSD between the normal and hypothyroid individuals 
before therapy as well as after therapy was not significant. 
 
 
 
 
 
 
 
 
 
 
 
Graph4. Comparison of HRV parameters- Time 
domain measures among study groups 
4a. Mean HR/min 
 
4b. Mean RR(ms) 
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TABLE-VI   Comparison of Frequency Domain measures of HRV 
Parameters Study groups N Mean  ±  SD P value 
LF (nu) 
Group A 30 40.77 ± 5.63 
0.000*** 
Group BBT 30 62.33 ± 9.02 
Group BBT 30 62.33 ± 9.02 
0.000*** 
Group BAT 30 41.99 ± 5.95 
HF (nu) 
Group A 30 59.23 ± 5.62 
0.000*** 
Group BBT 30 37.07 ± 9.24 
Group BBT 30 37.07 ± 9.24 
0.000*** 
Group BAT 30 58.01 ± 5.94 
LF HF 
Ratio 
Group A 30 00.70 ± 0.16 
0.000*** 
Group BBT 30 01.91 ± 0.98 
Group BBT 30 01.91 ± 0.98 
0.000*** 
Group BAT 30 00.75 ± 0.18 
TOTAL 
Power 
(ms
2
) 
Group A 30 2546.23 ± 447.98 
0.000*** 
Group BBT 30 1991.9 ± 545.26 
Group BBT 30 1991.9 ± 545.26 
0.508 
Group BAT 30 2084.7 ± 556.06 
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TABLE-VI shows comparison of Frequency domain measures of Resting 
HRV among study groups. The mean value of LF(nu), HF(nu), LF/HF 
ratio, Total power among the normal and hypothyroid individuals before 
and after therapy was very highly significant except the total power which 
did not showed significant difference  after L-thyroxine therap. 
  
Graph5. Comparison of HRV parameters- Frequency 
domain measures among study groups 
5a. LF (nu) 
 
5b. HF (nu) 
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DISCUSSION 
 Hypothyroidism has been found to be associated with increased 
cardiovascular morbidity and mortality. It affects cardiac structure, 
function, as well as cardiovascular hemodynamics (Hills LD, Lange RA, 
Winniford MD, Page RL et al)
84
. Cardiac manifestations of 
hypothyroidism includes decreased heart rate, increased peripheral 
resistance, decreased cardiac output, decreased myocardial contractility, 
and disturbances in autonomic function. 
  This study was primarily to analyze the cardiac autonomic 
function in newly diagnosed hypothyroid female individuals by doing Heart 
Rate Variability Analysis and Echocardiography and the impact of L 
thyroxine over these parameters. Thirty newly diagnosed hypothyroid 
female subjects (with elevated serum TSH levels above 10mIU/ml) and 
thirty age matched normal controls were included in our study. After 
evaluating with HRV and ECHO the hypothyroid subjects were started on 
L thyroxine for a minimum of three months and serum TSH levels were 
measured after three months. After attaining euthyroid levels of serum TSH 
(0.5-5.5mIU/ml), the subjects were reassessed with HRV and ECHO. All 
the parameters were compared after therapy with L thyroxine. 
 The study groups were selected at an age group of 20 to 35 years to 
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alleviate the effects of ageing on autonomic dysfunction. The mean age of 
the control group was 27.50±3.37 and that of the Hypothyroid group was 
27.23±3.77. The difference was not significant and so both the study groups 
are age matched. This was in accordance with the earlier studies where the 
selected study groups were at a similar age group. 
Comparison of BMI in hypothyroidism  
The body mass index (BMI) was calculated from the height and weight of 
the individuals by the formula weight (kg)/height in meters
2
. The mean 
BMI of normal group was 25.97± 1.37 and the mean BMI of the 
hypothyroid individuals was 26.32±2.08, which was found to be 
statistically not significant. This was consistent with studies done by (S. 
Karthick et al, G.K. Pal et al)
85
. 
 Resting Heart Rate and  Blood Pressure in Hypothyroidism. 
The mean Resting HR of the hypothyroid individuals before treatment was 
significantly lower than controls. An elevated level of sympathetic and 
decreased level of vagal modulation is expected in hypothyroidism. 
(Cacciatori, Galetta, Frazoni F, Sahin et al)
86
. The mean HR of 
hypothyroid group was significantly lower than the normal control group. 
The possible reason for this could be sympathetic over activity. The mean 
Resting HR in hypothyroid subjects after treatment with L –thyroxine 
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showed statistically significant increase when compared with before 
treatment.  
The Resting systolic blood pressure did not showed statistically 
significant difference among the normal and hypothyroid individuals before  
and after therapy. This was also found in study done by (S. Karthick et al, 
G.K. Pal et al)
85
. But there was a mild increase in diastolic blood pressure 
which was also found by (Anjali Nadir Bhat et al, Leela Kalsotra et 
al)
86
.This could explain that there may be an increase in peripheral vascular 
resistance in hypothyroidism as suggested by(Klein and Ojamaa et al 
2000)
37
.  According to (Fommei et al)
39
, the decrease in thyroid 
hormone may cause the elevation of blood pressure levels and also 
triggering of sympathetic/adrenal system. This can be handled with 
replacement of thyroid hormone. The SBP and DBP can also be reduced 
with thyroxine therapies.  
 Serum TSH levels in hypothyroidism 
 In our study the serum TSH levels among the study groups were estimated 
by the ELISA method. A considerable amount of increase in mean serum 
levels of TSH is seen in people with hypothyroid than the normal group and 
this was found in the study done by (S. Karthick et al, G.K. Pal et al)
85
. 
After therapy with L-thyroxine the serum TSH levels was found to be 
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decreased to statistically significant levels which was also observed with 
study done by (Vijayalakshmi et al, N. Vaney et al, S. V. Madhu et al)
14
. 
Resting Heart Rate Variability. 
Heart Rate Variability (HRV) analysis is one of the effective, non- 
invasive tool to assess the ANS function. There is an increased risk of 
adverse cardiac events in association with altered resting HRV. Analysis of 
the resting heart rate variability of a 5 minutes recording done using the 
HRV analysis software version1.1 among the study groups showed the 
following results. 
Time domain measures: 
Mean RR, Mean HR, SDNN, RMSSD were the variables taken for 
analysis as prescribed by the Task force
74
. Our findings showed decreased 
HRV in hypothyroid subjects. Decreased HRV is suggestive of either 
increased sympathetic tone or decreased parasympathetic tone. The Mean 
HR was significantly decreased in the hypothyroid individuals when 
compared to normal controls before treatment and it statistically improved 
after treatment with L thyroxine. The Mean RR among the study groups 
were measured which shows increased mean RR interval in the hypothyroid 
individuals before treatment when compared with normal controls. This 
shows relative bradycardia in the hypothyroid individuals as the mean RR 
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interval is inversely related with heart rate. Our findings were also observed 
in studies done by (Galetta F et al, Franzoni F et al)
87
. There was also 
minimal increase in mean RR intervals after treatment with L-thyroxine 
which was observed with earlier reporting of (Inukai et al and 
Kahaly)
45,46
.    
In our study hypothyroid individuals showed decreased mean values 
of SDNN and RMSSD when compared with the normal controls. This was 
also observed with (S. Karthick et al, G.K. Pal et al)
85
. There was also  
mild increase in SDNN  and RMSSD after treatment with L- thyroxine. Our 
findings were in accordance with (Galetta F, Franzoni F, Fallahi P et 
al)
87
 who showed that the resting time domain measures were significantly 
lower in hypothyroid individuals and  statistically improved after 
replacement with L-thyroxine. The SDNN, RMSSD were considered as 
sensitive indicators of parasympathetic function and thereby a low value 
indicates reduced vagal activity in hypothyroid individuals. 
Frequency Domain Measures: 
A significant variation in the frequency domain variables was observed 
among the study groups. The LF values which is an indicator of 
sympathetic tone was significantly higher in hypothyroid group when 
comparing with normal controls. The HF values in normalized units(nu) 
which is an indicator of parasympathetic tone was found to be significantly 
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lower in hypothyroid individuals before treatment when compared with 
normal controls This was found to be consistent with findings of (Vittorio 
Cacciatori et al)
87
.  
 As the HF power is considered to be strictly under vagal activity, 
our findings suggests that there is decreased parasympathetic activity in 
hypothyroidism which were in line with earlier observations from (Inukai 
et al)
16
.  Moreover there was also restoration of the efferent vagal activity 
as evidenced by increase in HF power after treatment which indicates 
increased sympathetic to vagal nerve transportation to the heart in 
hypothyroid individuals.  
A considerable increase in LF/HF ratio is seen in hypothyroid 
individuals before the treatment and the same is due to sympathovagal 
balance. This was also consistent with the reports from (Galetta F, 
Franzoni F, Fallahi P, Tocchini L et al)
86
, who observed decreased HF, 
increased LF amplitude, increased LF/HF ratio in untreated hypothyroid 
individuals and significantly improved HF amplitude and comparable 
LF/HF ratios after treatment with replacement therapy with L thyroxine. 
 Our findings are consistent with prior studies of (Cacciatori V, 
Sahin I, Turan N, Nielsen HV, Manhem P, Bramnert M, Bhat AN, 
Kalsotra L)
59,53,55,52
 who were observed significantly higher LF/HF ratio in 
hypothyroid individuals compared to control. Similar findings also found 
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by (Matia Ahmed, Noorzahan Begum et al)
58
 in the hypothyroid subjects 
when compared with controls and treated hypothyroid patients. 
 It was found that reduction in vagal modulation and elevation in 
sympathetic happens with hypothyroidism. But key features of 
hypothyroidism are decreased HR. This is due to desensitization of receptor 
and also due to decreased cardiac chronotropic that refers to adrenergic 
stimulation although evidence of sympathetic over activity. This also 
explains the other features of hypothyroidism like increased peripheral 
resistance and increased diastolic blood pressure, peripheral 
vasoconstriction and cold intolerance in these individuals. The cardio 
vascular effects and changes in hypothyroidism is due to reduction in 
binding of catecholamine along with beta and alpha receptors of the cardiac 
myocytes (Galetta et al)
87
. 
 Total power in HRV indicates overall variability of RR interval and 
whole cardiac autonomic nervous actions and hormonal actions on the heart 
(Task force). In our study there is decreased total power prior to 
hypothyroid treatment when compared to normal control group which was 
in consistent with those observed by (Caccitori, Galetta et al, Sahin 
Turan et al)
52,53,55
. There is also improvement in the total power after 
treatment with L thyroxine which was observed in their studies. 
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Echocardiography in hypothyroidism 
As echocardiography, which is also a non – invasive method plays 
an significant action in identifying the cardiac pathology and for the 
subsequent effect of the therapy (Rodondi N, Bauer D.C., Cappola A.R., 
et al)
79
. In the present study we carried out an investigation of cardiac 
function in patients with newly diagnosed hypothyroid female individuals 
and followed up after attaining euthyroid state with L thyroxine 
replacement therapy. The ECHO parameter especially the ejection fraction 
and LVID (end systolic and diastolic together) were compared with those 
of normal controls after therapy. 
Our present study showed very highly significant decrease in 
ejection fraction in hypothyroid individuals when compared with normal 
controls. It was also improved after treatment with L thyroxine almost to 
normal range with very high significant pvalue of 0.000. This was in 
accordance with previous studies done by (Rawat B, Satyal A, Monzani 
F, Bello VD, Caraccio N et al)
88
. 
The left ventricular internal diameter together with end systolic and 
end diastolic dimensions are taken in cms. There were stastically significant 
differences in the parameters among the study groups that is between 
normal and hypothyroid individuals before and  after therapy with L 
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thyroxine treatment. Our findings are consistent with those observed by 
(Rawat B, Satya et al)
88
. 
In the present study, based on the discussion, we observed a 
substantial fall in total power in hypothyroid patients in relation to normal 
controls from the spectral frequency domain analysis for HRV. This 
reduction in total power reflects the reduced vagal modulation in the 
individuals. (Alberto M et al, Task force of European Society)
89
. This 
finding contradicts with those observed by Xing et al
54
. According to Xing, 
high HF values in hypothyroid individuals have elevated vagal tone with 
autonomic imbalance. Xing et al
54
 found HF more than the LF segment. 
But in our study, it showed decreased HF than LF, which denotes reduced 
vagal activity. We observed that the difference in observation is may be due 
to different sample size. 
 It is also observed that the contribution of HF is higher than the LF - 
VF components with the ratio of two third to one third respectively. This 
explains the reduction in vagal activities due to decreased HF power in the 
hypothyroid individuals may result in reduced total power. 
The normal cardiovascular health of the individuals is determined by 
vagal activity on the heart. Hence vagal innervation has got greater 
influence on the control of heart rate, BP and cardia output. Our study 
shows increased LF power in the hypothyroid individuals which was also 
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reported by Cacciatori et al
52
. The most probable reason for that may be 
due to increased sympathetic activity on the heart..  
Thus the results of the resting heart rate variability in hypothyroid 
individuals differed noticeably from the results of those obtained in the 
normal individuals. This represents a sympathovagal imbalance in 
hypothyroid individuals with sympathetic over activity and altered 
functional status of the heart as shown by ECHO parameters. Both these 
altered functional status and sympathovagal imbalance can be improved by 
early replacement therapy with L thyroxine.  This could prevent the 
cardiovascular complications of hypothyroidism like cardiac arrhythmias in 
these patients.     
 
LIMITATIONS OF THE STUDY 
Our study was done in a smaller sample size. It is necessary to 
substantiate our findings and apply it to a general population studies using 
larger sample size. All the women were selected in the 20-35 years of age. 
So in order to generalize the findings, larger studies including wide age 
groups should be included. 
This study was conducted on newly diagnosed hypothyroid female 
individuals who were not on any treatment in whom the duration of the 
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disease was not known. So we could not find any correlation between the 
duration of the disease and autonomic dysfunction. 
The study had a drawback, as it evaluated only the resting autonomic 
activity and not the response of the autonomic nervous system to various 
external stimuli or lab stressors. 
The mechanisms suggested for autonomic dysfunction in 
hypothyroidism are an elevated circulating nor epinephrine levels with 
reduced sensitivity of the receptors to the stimuli. Hence our observations 
need to be substantiated by measurements of the catecholamine nor 
epinephrine levels which will not be feasible here. 
From this study, ultimately we understood that  autonomic 
imbalance could be a risk factor for cardiovascular morbidity among 
hypothyroid individuals and it could be prevented by adequate replacement 
therapy with L thyroxine. 
 
 
 
 
 
  
 
 
 
 
CONCLUSION 
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CONCLUSION 
  The cardiovascular autonomic nervous system activity 
and functional status of the heart were evaluated in newly diagnosed 
hypothyroid female individuals using Resting Heart rate variability 
analysis and Echocardiographic study before starting on treatment. Further 
the subjects are followed with 3 months of replacement therapy with L 
thyroxine. After obtaining euthyroid state the subjects were reevaluated 
again and the observed parameters were compared.    
This study concludes an autonomic imbalance as evidenced by 
decrease in SDNN, RMSSD which were indicators of parasympathetic 
activity in hypothyroid individuals before treatment and increase in LF 
power (nu) showing the sympathetic activity. The ratio between LF and HF 
was increased in hypothyroid individuals before treatment which showed 
sympathetic dominance of autonomic nervous system activity. The total 
power is also decreased in hypothyroid individuals when compared to 
normal controls. 
 When analyzing the Echocardiographic parameters there is decrease 
in ejection fraction and there were differences in LVID (end systolic, end 
diastolic). This shows altered structural and functional status of the heart in 
hypothyroidism. 
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 All these parameters showed significant improvement after 
replacement therapy with L thyroxine.   
       
  
  
 
 
 
 
SUMMARY 
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   SUMMARY 
 Hypothyroidism is a common endocrine disorder with female 
preponderance. It is known to be associated with autonomic dysfunction 
and cardiovascular risks like hypertension, atherosclerosis, and 
arrhythmias. We aimed to evaluate the autonomic system activity by using 
Resting heart rate variability analysis and echocardiography in newly 
diagnosed (clinically as well as biochemically with elevated serum TSH 
levels) female hypothyroid individuals. 
Thirty female hypothyroid individuals in the age group of 20-35 years with 
age matched healthy females were taken as controls. Both of them 
subjected to Resting HRV and ECHO. The cases were followed up after 3 
months of replacement therapy with L thyroxine. Reassessedwith HRV and 
ECHO after attaining euthyroid state. 
 Analysis of the data obtained from the study, showed that 
hypothyroidism is associated with autonomic dysfunction in the form of 
increased sympathetic activity and decreased parasympathetic activity 
compared to their controls with altered functional status of the heart as 
evidenced by echocardiography. This could be improved by replacement 
therapy with L thyroxine as which was shown by reassessing the cases after 
treatment. 
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.All these observation suggests that sympathetic over activity with 
decreased parasympathetic activity in hypothyroidism might be responsible 
for the pathogenesis of cardiovascular features associated with 
hypothyroidism. 
And improvement in HRV and echo parameters after treatment with 
L thyroxine shows that the cardiovascular autonomic function can be 
maintained with adequate replacement therapy in hypothyroidism and 
potential cardiovascular risks associated with it can be prevented by regular 
follow up of these individuals with these noninvasive tests. 
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